These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 26214805)
1. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. Hansen K; Schüssel K; Kieble M; Werning J; Schulz M; Friis R; Pöhlau D; Schmitz N; Kugler J PLoS One; 2015; 10(7):e0133279. PubMed ID: 26214805 [TBL] [Abstract][Full Text] [Related]
2. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501 [TBL] [Abstract][Full Text] [Related]
3. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Reynolds MW; Stephen R; Seaman C; Rajagopalan K Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144 [TBL] [Abstract][Full Text] [Related]
4. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. Kleinman NL; Beren IA; Rajagopalan K; Brook RA J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113 [TBL] [Abstract][Full Text] [Related]
5. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). Moccia M; Loperto I; Lanzillo R; Capacchione A; Carotenuto A; Triassi M; Brescia Morra V; Palladino R BMC Health Serv Res; 2020 Aug; 20(1):797. PubMed ID: 32847587 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania. Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690 [TBL] [Abstract][Full Text] [Related]
7. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Steinberg SC; Faris RJ; Chang CF; Chan A; Tankersley MA Clin Drug Investig; 2010; 30(2):89-100. PubMed ID: 20067327 [TBL] [Abstract][Full Text] [Related]
8. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581 [TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169 [TBL] [Abstract][Full Text] [Related]
10. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542 [TBL] [Abstract][Full Text] [Related]
11. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment. Lage MJ; Carroll CA; Fairman KA J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620 [TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. Reynolds MW; Stephen R; Seaman C; Rajagopalan K J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189 [TBL] [Abstract][Full Text] [Related]
13. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region]. Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Oleen-Burkey M; Cyhaniuk A; Swallow E J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Sabanov AV; Luneva AV; Matveev NV Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963 [TBL] [Abstract][Full Text] [Related]
16. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190 [TBL] [Abstract][Full Text] [Related]
17. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879 [TBL] [Abstract][Full Text] [Related]
18. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292 [TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760 [TBL] [Abstract][Full Text] [Related]